Neurobiology of depression: an integrated view of key findings

V Maletic, M Robinson, T Oakes, S Iyengar, S G Ball, J Russell, V Maletic, M Robinson, T Oakes, S Iyengar, S G Ball, J Russell

Abstract

Aims: The objectives of the present review were to summarise the key findings from the clinical literature regarding the neurobiology of major depressive disorder (MDD) and their implications for maximising treatment outcomes. Several neuroanatomical structures in the prefrontal and limbic areas of the brain are involved in affective regulation. In patients with MDD, alterations in the dynamic patterns of activity among these structures have profound implications for the pathogenesis of this illness.

Discussion: The present work reviews the evidence for the progressive nature of MDD along with associated changes in neuroanatomical structure and function, especially for the hippocampus. The role of glucocorticoids, inflammatory cytokines and brain-derived growth factors are discussed as mediators of these pathological alterations. From this integrated model, the role of antidepressant therapy in restoring normative processes is examined along with additional treatment guidelines.

Conclusion: Major depressive disorder is an illness with significant neurobiological consequences involving structural, functional and molecular alterations in several areas of the brain. Antidepressant pharmacotherapy is associated with restoration of the underlying physiology. Clinicians are advised to intervene with MDD using an early, comprehensive treatment approach that has remission as the goal.

Figures

Figure 1
Figure 1
Major depression as a progressive illness. As the number of major depressive episodes increase, the risk for subsequent episodes is predicted more from the number of prior episodes and less from the occurrence of a recent life stress. Figure adapted from ref. no. (14)
Figure 2
Figure 2
Major depressive disorder affects the dynamic connectivity among neuroanatomical structures involved in regulation of mood and stress response. Limbic structures (amygdala, hippocampus and nucleus accumbens) have reciprocal connections with ‘para-limbic’ cortical areas, subgenual anterior cingluate and ventromedial prefrontal cortex (VMPFC). Hypothetically, disrupted ‘connectivity’ between limbic/para-limbic areas and rostral integrative prefrontal formations, results in compromised feedback regulation of limbic activity. Consequently, dorsal cognitive/executive network is hypoactive while overly active limbic areas continue to stimulate the hypothalamus leading to neuroendocrine dysregulation and sympathetic hyperactivity
Figure 3
Figure 3
Molecular processes are impacted by stress and depression. Stress results in release of glucocorticoids and corticotrophin releasing hormones (CRH) and pro-inflammatory cytokines (TNF, IL-1, IL-6). In depression, disruption of serotonin (5-HT), norepinephrine (NE) and dopamine (DA) transmission impair the regulatory feedback loops that ‘turn off’ the stress response. Sympathetic overactivity contributes to immune activation and release of inflammatory cytokines. Inflammatory cytokines further interfere with monoaminergic and neurotrophic signalling. They may also diminish central corticosteroid receptor sensitivity, leading to disruption of feedback control. Figure adapted from ref. no. (46)
Figure 4
Figure 4
Antidepressant therapy is associated with restoring normative processes. Treatment with various selective serotonin antidepressant treatments and serotonergic noradrenergic reuptake inhibitors resulted in increases in serum brain-derived neurotrophic factor (BDNF) for patients with MDD to levels comparable that were observed with healthy controls. Reprinted with copyright permission from ref. no. (66)

References

    1. Remick RA. Diagnosis and management of depression in primary care: a clinical update and review. Can Med Assoc J. 2002;167:1253–60.
    1. Nemeroff CB. The burden of severe depression: a review of diagnostic challenges and treatment alternatives. J Psychiatr Res. 2007;41:189–206.
    1. Castren E. Is mood chemistry. Nat Rev Neurosci. 2005;6:241–6.
    1. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006;59:1116–27.
    1. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R) JAMA. 2003;289:3095–105.
    1. McGlinchey JB, Zimmerman M, Young D, Chelminski I. Diagnosing major depressive disorder VII: are some symptoms better than others. J Nerv Ment Dis. 2006;194:785–90.
    1. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders-Fourth Edition, Text-Revision. Washington, DC: American Psychiatric Press; 2000.
    1. Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156:1000–6.
    1. Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry. 2000;157:229–33.
    1. Hollon SD, Shelton RC, Wisniewski S, et al. Presenting characteristics of depressed outpatients as a function of recurrence: preliminary findings from the STAR*D clinical trial. J Psychiatr Res. 2006;40:59–69.
    1. Post RM, Rubinow DR, Ballenger JC. Conditioning and sensitisation in the longitudinal course of affective illness. Br J Psychiatry. 1986;149:191–201.
    1. Kendler KS, Thornton LM, Gardner CO. Stressful life events and previous episodes in the etiology of major depression in women: an evaluation of the “kindling” hypothesis. Am J Psychiatry. 2000;157:1243–51.
    1. Monroe SM, Harkness KL. Life stress, the ‘‘kindling’’ hypothesis, and the recurrence of depression: considerations from a life stress perspective. Psychol Rev. 2005;112:417–45.
    1. Kendler KS, Thornton LM, Gardner CO. Genetic risk, number of previous depressive episodes, and stressful life events in predicting the onset of major depression. Am J Psychiatry. 2001;158:582–6.
    1. Ladd CO, Huot RL, Thrivkraman KV, Nemeroff CB, Meany MJ, Plotsky PM. Long-term behavioral and neuroendocrine adaptations to adverse early experience. Prog Brain Res. 2000;122:81–103.
    1. Kaufman J, Yang BZ, Douglas-Palumberi H, et al. Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biol Psychiatry. 2006;59:673–80.
    1. Heim C, Plotsky PM, Nemeroff CB. Importance of studying the contributions of early adverse experience to neurobiological findings in depression. Neuropsychopharmacology. 2004;29:641–8.
    1. McCullough JP, Jr, Klein DN, Borian FE, et al. Group comparisons of DSM-IV subtypes of chronic depression: validity of the distinctions, part 2. J Abnorm Psychol. 2003;112:614–22.
    1. Keller MB, Lavori PW, Mueller TI, et al. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry. 1992;49:809–16.
    1. Spijker J, de Graaf R, Bijl RV, et al. Determinants of persistence of major depressive episodes in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS) J Affect Disord. 2004;81:231–40.
    1. Buist-Bouwman MA, Ormel J, de Graaf R, Vollebergh WAM. Functioning after a major depressive episode: complete or incomplete recovery. J Affect Disord. 2004;82:363–71.
    1. Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord. 1998;50:97–108.
    1. Keller MB. Past, present, and future directions for defining optimal treatment outcome in depression: remission and beyond. JAMA. 2003;289:3152–60.
    1. Drevets WC. Functional neuroimaging studies of depression: the anatomy of melancholia. Annu Rev Med. 1998;49:341–61.
    1. Davidson RJ. Affective neuroscience and psychophysiology: toward a synthesis. Psychophysiology. 2003;40:655–65.
    1. Swanson LW. The hypothalamus. In: Björklund A, Hökfelt T, Swanson LW, editors. Handbook of Chemical Neuroanatomy, Vol. 5, Integrated Systems of the CNS, Part I, Hypothalamus, Hippocampus, Amygdala, Retina. New York, NY: Elsevier; 1987. pp. 1–124.
    1. Bush G, Luu P, Posner MI. Cognitive and emotional influences in anterior cingulate cortex. Trends Cogn Sci. 2000;4:215–22.
    1. McCormick LM, Ziebell S, Nopoulos P, et al. Anterior cingulated cortex: an MRI-based parcellation method. Neuroimage. 2006;32:1167–75.
    1. Anand A, Li Y, Wang Y, et al. Activity and connectivity of brain mood regulating circuit in depression: a functional magnetic resonance study. Biol Psychiatry. 2005;57:1079–88.
    1. Whittle S, Allen NB, Lubman DI, Yücel M. The neurobiological basis of temperament: towards a better understanding of psychopathology. Neurosci Biobehav Rev. 2005;30:511–25.
    1. MacDonald AW, III, Cohen JD, Stenger VA, Carter CS. Dissociating the role of the dorsolateral prefrontal and anterior cingulate cortex in cognitive control. Science. 2000;288:1835–8.
    1. Videbech P, Ravnkilde B. Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry. 2004;161:1957–66.
    1. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160:1516–8.
    1. Colla M, Kronenberg G, Deuschle M, et al. Hippocampal volume reduction and HPA-system activity in major depression. J Psychiatr Res. 2007;41:553–60.
    1. Neumeister A, Wood S, Bonne O, et al. Reduced hippocampal volume in unmedicated, remitted patients with major depression versus control subjects. Biol Psychiatry. 2005;57:935–7.
    1. Lyons DM, Yang C, Sawyer-Glover AM, Moseley ME, Schatzberg AF. Early life stress and inherited variation in monkey hippocampal volumes. Arch Gen Psychiatry. 2001;58:1145–51.
    1. Sullilvan EV, Pfefferbaum A, Swan GE, Carmelli D. Heritability of hippocampal size in elderly twin men: equivalent influence from genes and environment. Hippocampus. 2001;11:754–62.
    1. Frodl T, Meisenzahl EM, Zill P, et al. Reduced hippocampal volumes associated with the long variant of the serotonin transporter polymorphism in major depression. Arch Gen Psychiatry. 2004;61:177–83.
    1. Frodl T, Schüle C, Schmitt G, et al. Association of the brain-derived neurotrophic factor Val66Met polymorphism with reduced hippocampal volumes in major depression. Arch Gen Psychiatry. 2007;64:410–6.
    1. Frodl T, Meisenzahl EM, Zetzsche T, et al. Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. J Clin Psychiatry. 2004;65:492–9.
    1. Manji HK, Quiroz JA, Sporn J, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry. 2003;53:707–42.
    1. de Kloet ER, Derijk RH, Meijer OC. Therapy insight: is there an imbalanced response of mineralcorticoid and glucocorticoid receptors in depression. Nat Clin Pract Endocrinol Metab. 2007;3:168–79.
    1. Nestler EJ, Barrot M, DiLeone RJ, et al. Neurobiology of depression. Neuron. 2002;34:13–25.
    1. Stockmeier CA, Mahajan GJ, Konick LC, et al. Cellular changes in the postmortem hippocampus in major depression. Biol Psychiatry. 2004;56:640–50.
    1. Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry. 2003;160:1554–65.
    1. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31.
    1. Weisler-Frank J, Maier SF, Watkins LR. Immune-to-brain communication dynamically modulates pain: physiological and pathological consequences. Brain Behav Immun. 2005;19:104–11.
    1. Tsigos C, Chrousos GP. Hypothalamic-pituitary-adrenal axis, neuroendocrine factors, and stress. J Psychosom Res. 2002;53:865–71.
    1. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 2007;6:219–33.
    1. Bessis A, Bechade C, Bernard D, Roumier A. Microglial control of neuronal death and synaptic properties. Glia. 2007;55:233–8.
    1. Frank MG, Baratta MV, Sprunger DB, Watkins LR, Maier SF. Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses. Brain Behav Immun. 2007;21:47–59.
    1. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597–606.
    1. Tapia-Arancibia L, Rage F, Givalois L, Arancibia S. Physiology of BDNF: focus on hypothalamic function. Front Neuroendocrinol. 2004;25:77–107.
    1. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat Rev Neurosci. 2005;6:603–14.
    1. Duric V, McCarson KE. Hippocampal neurokinin-1 receptor and brain-derived neurotrophic factor gene expression is decreased in rat models of pain and stress. Neuroscience. 2005;133:999–1006.
    1. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003;54:70–5.
    1. Karege F, Vaudan G, Schwald M, et al. Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res. 2005;136:29–37.
    1. Meyer JH, Ginovart N, Boovariwala A, et al. Elevated monoamine oxidase A levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006;63:1209–16.
    1. Mega MS, Cummings JL, Salloway S, Malloy P. The limbic system: an anatomic, phylogenetic, and clinical perspective. J Neuropsychiatry Clin Neurosci. 1997;9:315–30.
    1. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu Rev Neurosci. 1991;14:219–45.
    1. Pace TWW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain Behav Immun. 2007;21:9–19.
    1. Juric DM, Miklic S, Carman-Krzan M. Monominergic neuronal activity up-regulates BDNF synthesis in cultured neonatal rat astrocytes. Brain Res. 2006;1108:54–62.
    1. Karege F, Schwald M, Cisse M. Postnatal development profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett. 2002;328:261–4.
    1. Lommatzsch M, Zingler D, Schuhbaeck K, et al. The impact of age, weight, and gender on BDNF levels in human platelets and plasma. Neurobiol Aging. 2005;26:115–23.
    1. Aydemir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29:261–5.
    1. Gonul AS, Akdeniz F, Taneli F, et al. Effect of treatment on serum brain-derived neurotrophic factor levels in depressed patients. Eur Arch Psychiatry Clin Neurosci. 2005;255:381–6.
    1. Chen B, Dowlatshahi D, MacQueen GM, et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry. 2001;50:260–5.
    1. Mayberg HS, Brannan SK, Tekell JL, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry. 2000;48:830–43.
    1. Sheline YI, Barch DM, Donnelly JM, et al. Increased amygdala response to masked emotional faces in depressed subjects resolves with antidepressant treatment: an fMRI study. Biol Psychiatry. 2001;50:651–8.
    1. Chen CH, Ridler K, Suckling J, et al. Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry. 2007;62:407–14.
    1. O'Brien SM, Scully P, Fitzgerald P, et al. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res. 2007;41:326–31.
    1. Brody AL, Saxena S, Mandelken MA, et al. Brain metabolic changes associated with symptom factor improvement in major depressive disorder. Biol Psychiatry. 2001;50:171–8.
    1. Duman RS. Neurotrophic factors and regulation of mood: role of exercise, diet, and metabolism. Neurobiol Aging. 2005;26(Suppl. 1):S88–93.
    1. Szádóczky E, Rozsa S, Zambori J, Furedi J. Predictors for 2 year outcome of major depressive episode. J Affect Disord. 2004;83:49–57.
    1. Tew JD, Mulsant BH, Houck PR, et al. Impact of prior treatment exposure on response to antidepressant treatment in late life. Am J Geriatr Psychiatry. 2006;14:957–65.
    1. Oswald P, Souery D, Kasper S, et al. Predictive factors of resistance to antidepressant treatment: results from a European multicentre study. Eur Neuropsychopharmacol. 2005;15(Suppl. 3):S326–7.
    1. Brook OH, van Hout HPJ, Stalman WAB, de Haan M. Nontricylic antidepressants: predictors of nonadherence. J Clin Psychopharmacol. 2006;26:643–7.
    1. Nelson JC, Mazure CM, Jatlow PI, et al. Combining norepinephrine and serotonin reuptake inhibition mechanism for treatment of depression: a double-blind, randomized study. Biol Psychiatry. 2004;55:296–300.
    1. Papakostas GI, Thase ME, Fava M, Nelson JC, Shelton RC. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Biol Psychiatry. 2007 doi: 10.1016/j.biopsych2007.03.027.
    1. Anderson I. Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J Affect Dis. 2000;58:19–36.
    1. Trivedi MH, Fava M, Marangell LB, et al. Use of treatment algorithms for depression. Prim Care Companion J Clin Psychiatry. 2006;8:291–7.
    1. Bair MJ, Robinson RL, Katon W, Kroenke K. Depression and pain comorbidity: a literature review. Arch Intern Med. 2003;163:2433–45.
    1. Karp JF, Scott J, Houck P, et al. Pain predicts longer time to remission during treatment of recurrent depression. J Clin Psychiatry. 2005;66:591–7.
    1. Greco T, Eckert G, Kroenke K. The outcomes of physical symptoms with treatment of depression. J Gen Intern Med. 2004;19:813–8.
    1. Jones CK, Eastwood BJ, Need AB, Shannon HE. Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibitors. Neuropharmacology. 2006;51:1172–80.
    1. Fava M, Mallinckrodt CH, Detke MJ, et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates. J Clin Psychiatry. 2004;65:521–30.
    1. Pintor L, Gastó C, Navarro V, et al. Relapse of major depression after complete and partial remission during a 2-year follow-up. J Affect Disord. 2003;73:237–44.
    1. Menza M, Marin H, Opper RS. Residual symptoms in depression: can treatment be symptom-specific. J Clin Psychiatry. 2003;64:516–23.
    1. Paykel ES, Scott J, Cornwall PL, et al. Duration of relapse prevention after cognitive therapy in residual depression: follow-up of controlled trial. Psychol Med. 2005;35:59–68.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren